Published in JACC Cardiovasc Imaging on August 01, 2010
Suppression of inflammation in a mouse model of rheumatoid arthritis using targeted lipase-labile fumagillin prodrug nanoparticles. Biomaterials (2012) 0.93
Blood oxygen level dependent angiography (BOLDangio) and its potential applications in cancer research. NMR Biomed (2012) 0.81
Molecular MRI of Inflammation in Atherosclerosis. Curr Cardiovasc Imaging Rep (2011) 0.81
Vasa vasorum in atherosclerosis and clinical significance. Int J Mol Sci (2015) 0.81
Perfluorocarbon nanoparticles: evolution of a multimodality and multifunctional imaging agent. Scientifica (Cairo) (2014) 0.79
Identification of High-Risk Plaques by MRI and Fluorescence Imaging in a Rabbit Model of Atherothrombosis. PLoS One (2015) 0.77
Recent Advances in (19)Fluorine Magnetic Resonance Imaging with Perfluorocarbon Emulsions. Engineering (Beijing) (2016) 0.75
Comparison of C-reactive protein and low-density lipoprotein cholesterol levels in the prediction of first cardiovascular events. N Engl J Med (2002) 16.23
C-reactive protein, the metabolic syndrome, and risk of incident cardiovascular events: an 8-year follow-up of 14 719 initially healthy American women. Circulation (2003) 6.99
Intraplaque hemorrhage and progression of coronary atheroma. N Engl J Med (2003) 5.43
Atherosclerotic plaque progression and vulnerability to rupture: angiogenesis as a source of intraplaque hemorrhage. Arterioscler Thromb Vasc Biol (2005) 4.29
Molecular imaging of angiogenesis in early-stage atherosclerosis with alpha(v)beta3-integrin-targeted nanoparticles. Circulation (2003) 3.68
Molecular imaging of angiogenesis in nascent Vx-2 rabbit tumors using a novel alpha(nu)beta3-targeted nanoparticle and 1.5 tesla magnetic resonance imaging. Cancer Res (2003) 2.70
Involvement of integrins alpha v beta 3 and alpha v beta 5 in ocular neovascular diseases. Proc Natl Acad Sci U S A (1996) 2.67
Endothelial alpha(v)beta3 integrin-targeted fumagillin nanoparticles inhibit angiogenesis in atherosclerosis. Arterioscler Thromb Vasc Biol (2006) 2.45
Neovascularization in human atherosclerosis. Circulation (2006) 2.44
Molecular MR imaging of melanoma angiogenesis with alphanubeta3-targeted paramagnetic nanoparticles. Magn Reson Med (2005) 2.30
Plaque neovascularization is increased in ruptured atherosclerotic lesions of human aorta: implications for plaque vulnerability. Circulation (2004) 2.30
Antiangiogenic synergism of integrin-targeted fumagillin nanoparticles and atorvastatin in atherosclerosis. JACC Cardiovasc Imaging (2008) 2.14
Noninvasive imaging of myocardial angiogenesis following experimental myocardial infarction. J Clin Invest (2004) 2.06
Pathologic assessment of the vulnerable human coronary plaque. Heart (2004) 1.88
Elimination of neoangiogenesis for plaque stabilization: is there a role for local drug therapy? J Am Coll Cardiol (2007) 1.78
Pathology of the thin-cap fibroatheroma: a type of vulnerable plaque. J Interv Cardiol (2003) 1.74
Minute dosages of alpha(nu)beta3-targeted fumagillin nanoparticles impair Vx-2 tumor angiogenesis and development in rabbits. FASEB J (2008) 1.67
Detection of injury-induced vascular remodeling by targeting activated alphavbeta3 integrin in vivo. Circulation (2004) 1.57
Granulocyte-macrophage and macrophage colony-stimulating factors differentially regulate alpha v integrin expression on cultured human macrophages. Proc Natl Acad Sci U S A (1993) 1.37
Improved molecular imaging contrast agent for detection of human thrombus. Magn Reson Med (2003) 1.37
Leucocyte recruitment in rupture prone regions of lipid-rich plaques: a prominent role for neovascularization? Cardiovasc Res (1999) 1.28
The activation state of alphavbeta 3 regulates platelet and lymphocyte adhesion to intact and thrombin-cleaved osteopontin. J Biol Chem (2000) 1.19
Nanoparticle pharmacokinetic profiling in vivo using magnetic resonance imaging. Magn Reson Med (2008) 1.19
Cardiovascular disease in the JCR:LA-cp rat. Mol Cell Biochem (1998) 1.00
The role of integrins in saphenous vein vascular smooth muscle cell migration. J Vasc Surg (1997) 0.98
Integrins in thrombosis, wound healing and cancer. Biochem Soc Trans (1991) 0.93
Glucose tolerance and insulin resistance in the JCR:LA-corpulent rat: effect of miglitol (Bay m1099). Metabolism (1999) 0.90
Plasma lipid secretion and clearance in hyperlipidemic JCR:LA-corpulent rats. Arteriosclerosis (1990) 0.90
Pair feeding-mediated changes in metabolism: stress response and pathophysiology in insulin-resistant, atherosclerosis-prone JCR:LA-cp rats. Am J Physiol Endocrinol Metab (2008) 0.80
Decreased serum lipids, serum insulin and triacylglycerol synthesis in adipose tissue of JCR:LA-corpulent rats treated with benfluorex. Biochim Biophys Acta (1991) 0.80
Antiatherogenic effects of long-term benfluorex treatment in male insulin resistant JCR:LA-cp rats. Atherosclerosis (1997) 0.79
Effects of benfluorex on serum triacylglycerols and insulin sensitivity in the corpulent rat. Can J Physiol Pharmacol (1996) 0.78
Independence of myocardial disease in the JCR:LA-corpulent rat on plasma cholesterol concentration. Clin Invest Med (1991) 0.78
Improvement of insulin sensitivity and cardiovascular outcomes in the JCR:LA-cp rat by D-fenfluramine. Diabetologia (1998) 0.78
Exosomes released by melanoma cells prepare sentinel lymph nodes for tumor metastasis. Cancer Res (2011) 3.73
Molecular imaging of angiogenesis in early-stage atherosclerosis with alpha(v)beta3-integrin-targeted nanoparticles. Circulation (2003) 3.68
Molecular imaging of angiogenesis in nascent Vx-2 rabbit tumors using a novel alpha(nu)beta3-targeted nanoparticle and 1.5 tesla magnetic resonance imaging. Cancer Res (2003) 2.70
19F magnetic resonance imaging for stem/progenitor cell tracking with multiple unique perfluorocarbon nanobeacons. FASEB J (2007) 2.63
Endothelial alpha(v)beta3 integrin-targeted fumagillin nanoparticles inhibit angiogenesis in atherosclerosis. Arterioscler Thromb Vasc Biol (2006) 2.45
Remodeling of cardiac fiber structure after infarction in rats quantified with diffusion tensor MRI. Am J Physiol Heart Circ Physiol (2003) 2.30
Molecular MR imaging of melanoma angiogenesis with alphanubeta3-targeted paramagnetic nanoparticles. Magn Reson Med (2005) 2.30
Antiangiogenic synergism of integrin-targeted fumagillin nanoparticles and atorvastatin in atherosclerosis. JACC Cardiovasc Imaging (2008) 2.14
Pooling data from multiple longitudinal studies: the role of item response theory in integrative data analysis. Dev Psychol (2008) 2.00
Regional ventricular wall thickening reflects changes in cardiac fiber and sheet structure during contraction: quantification with diffusion tensor MRI. Am J Physiol Heart Circ Physiol (2005) 1.91
Nanotechnological applications in medicine. Curr Opin Biotechnol (2007) 1.90
Targeted nanoparticles for quantitative imaging of sparse molecular epitopes with MRI. Magn Reson Med (2004) 1.83
Molecularly targeted nanocarriers deliver the cytolytic peptide melittin specifically to tumor cells in mice, reducing tumor growth. J Clin Invest (2009) 1.78
Targeted antiproliferative drug delivery to vascular smooth muscle cells with a magnetic resonance imaging nanoparticle contrast agent: implications for rational therapy of restenosis. Circulation (2002) 1.77
Practical value of cardiac magnetic resonance imaging for clinical quantification of aortic valve stenosis: comparison with echocardiography. Circulation (2003) 1.73
Quantitative "magnetic resonance immunohistochemistry" with ligand-targeted (19)F nanoparticles. Magn Reson Med (2004) 1.68
Minute dosages of alpha(nu)beta3-targeted fumagillin nanoparticles impair Vx-2 tumor angiogenesis and development in rabbits. FASEB J (2008) 1.67
High-resolution MR imaging of the human eye 2005. Acad Radiol (2006) 1.65
Paracrine induction of endothelium by tumor exosomes. Lab Invest (2009) 1.63
Computed tomography in color: NanoK-enhanced spectral CT molecular imaging. Angew Chem Int Ed Engl (2010) 1.57
Imaging of Vx-2 rabbit tumors with alpha(nu)beta3-integrin-targeted 111In nanoparticles. Int J Cancer (2007) 1.57
In vivo "hot spot" MR imaging of neural stem cells using fluorinated nanoparticles. Magn Reson Med (2008) 1.56
Noninvasive photoacoustic and fluorescence sentinel lymph node identification using dye-loaded perfluorocarbon nanoparticles. ACS Nano (2010) 1.53
RNA interference knockdown of DNA methyl-transferase 3 affects gene alternative splicing in the honey bee. Proc Natl Acad Sci U S A (2013) 1.49
Synthesis and characterization of stable fluorocarbon nanostructures as drug delivery vehicles for cytolytic peptides. Nano Lett (2008) 1.47
Molecular photoacoustic tomography with colloidal nanobeacons. Angew Chem Int Ed Engl (2009) 1.47
Synthesis of NanoQ, a copper-based contrast agent for high-resolution magnetic resonance imaging characterization of human thrombus. J Am Chem Soc (2011) 1.47
Molecular imaging and therapy of atherosclerosis with targeted nanoparticles. J Magn Reson Imaging (2007) 1.46
Targeted contrast agents for magnetic resonance imaging and ultrasound. Curr Opin Biotechnol (2005) 1.43
Molecular photoacoustic imaging of angiogenesis with integrin-targeted gold nanobeacons. FASEB J (2010) 1.42
Three-dimensional MR mapping of angiogenesis with alpha5beta1(alpha nu beta3)-targeted theranostic nanoparticles in the MDA-MB-435 xenograft mouse model. FASEB J (2008) 1.41
Perfluorocarbon nanoemulsions for quantitative molecular imaging and targeted therapeutics. Ann Biomed Eng (2009) 1.39
Nanotechnology for molecular imaging and targeted therapy. Circulation (2003) 1.38
Parent alcoholism impacts the severity and timing of children's externalizing symptoms. J Abnorm Child Psychol (2010) 1.37
Improved molecular imaging contrast agent for detection of human thrombus. Magn Reson Med (2003) 1.37
Harmonic phase MR tagging for direct quantification of Lagrangian strain in rat hearts after myocardial infarction. Magn Reson Med (2004) 1.35
T2 hypointensity in the deep gray matter of patients with multiple sclerosis: a quantitative magnetic resonance imaging study. Arch Neurol (2002) 1.35
Bleomycin-induced apoptosis of alveolar epithelial cells requires angiotensin synthesis de novo. Am J Physiol Lung Cell Mol Physiol (2002) 1.31
Ligand-directed nanobialys as theranostic agent for drug delivery and manganese-based magnetic resonance imaging of vascular targets. J Am Chem Soc (2008) 1.31